Universal radical cure: prospects and challenges for malaria elimination
- PMID: 37979596
- DOI: 10.1016/S0140-6736(23)01950-5
Universal radical cure: prospects and challenges for malaria elimination
Conflict of interest statement
This Comment was supported in part by the US National Institutes of Health (grant number R01AI177791 to AA and JBP). JBP reports grants from Gilead Sciences, non-financial support from Abbott Laboratories, and personal fees (consulting) from Zymeron Corporation, outside the submitted work.
Comment on
-
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.Lancet. 2023 Dec 2;402(10417):2101-2110. doi: 10.1016/S0140-6736(23)01553-2. Epub 2023 Nov 15. Lancet. 2023. PMID: 37979594 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
